- Home
- HCWB vs CRIS Comparison
HCWB vs CRIS Comparison
Compare HCWB & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- CRIS
- Stock Information
- Founded
- HCWB 2018
- CRIS 2000
- Country
- HCWB United States
- CRIS United States
- Employees
- HCWB N/A
- CRIS N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCWB Health Care
- CRIS Health Care
- Exchange
- HCWB Nasdaq
- CRIS Nasdaq
- Market Cap
- HCWB 26.6M
- CRIS 31.2M
- IPO Year
- HCWB 2021
- CRIS 2000
- Fundamental
- Price
- HCWB $0.31
- CRIS $4.00
- Analyst Decision
- HCWB
- CRIS Strong Buy
- Analyst Count
- HCWB 0
- CRIS 3
- Target Price
- HCWB N/A
- CRIS $23.00
- AVG Volume (30 Days)
- HCWB 96.6K
- CRIS 68.2K
- Earning Date
- HCWB 11-19-2024
- CRIS 11-14-2024
- Dividend Yield
- HCWB N/A
- CRIS N/A
- EPS Growth
- HCWB N/A
- CRIS N/A
- EPS
- HCWB N/A
- CRIS N/A
- Revenue
- HCWB $3,922,670.00
- CRIS $10,161,000.00
- Revenue This Year
- HCWB N/A
- CRIS N/A
- Revenue Next Year
- HCWB N/A
- CRIS N/A
- P/E Ratio
- HCWB N/A
- CRIS N/A
- Revenue Growth
- HCWB 2.82
- CRIS N/A
- 52 Week Low
- HCWB $0.28
- CRIS $3.70
- 52 Week High
- HCWB $1.93
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- HCWB 26.31
- CRIS 32.54
- Support Level
- HCWB $0.42
- CRIS $3.70
- Resistance Level
- HCWB $0.50
- CRIS $4.55
- Average True Range (ATR)
- HCWB 0.04
- CRIS 0.42
- MACD
- HCWB -0.01
- CRIS -0.04
- Stochastic Oscillator
- HCWB 4.39
- CRIS 23.70
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.